1. The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC 
Christian Manegold, MD, Anne-Marie C. Dingemans, MD, PhD, Jhanelle E. Gray, MD, Kazuhiko Nakagawa, MD, Marianne Nicolson, MD, Solange Peters, MD, PhD, Martin Reck, MD, PhD, Yi-Long Wu, MD, Odd Terje Brustugun, MD, PhD, Lucio Crinò, MD, Enriqueta Felip, MD, Dean Fennell, MD, PhD, Pilar Garrido, MD, PhD, Rudolf M. Huber, MD, Aurélien Marabelle, MD, PhD, Marcin Moniuszko, MD, Françoise Mornex, MD, PhD, Silvia Novello, MD, PhD, Mauro Papotti, MD, Maurice Pérol, MD, Egbert F. Smit, MD, PhD, Kostas Syrigos, MD, Jan P. van Meerbeeck, MD, Nico van Zandwijk, MD, PhD, James Chih-Hsin Yang, MD, Caicun Zhou, MD, PhD, Everett Vokes, MD 
Journal of Thoracic Oncology 
Volume 12, Issue 2, Pages (February 2017)
DOI: /j.jtho
Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

2. Figure 1
Combined inhibition of tumor angiogenesis and the immune checkpoint, programmed cell death protein 1 (PD-1). Abbreviations: Arg1, arginase 1; CD4, cluster of differentiation 4; CD8, cluster of differentiation 8; iDC, immature dendritic cell; IDO, indoleamine 2, 3-dioxygenase; IL-10, interleukin-10; iNOS, inducible nitric oxide synthase; MDSC, myeloid-derived suppressor cell; NK, natural killer; PD-L1, programmed death ligand 1; PGE2, prostaglandin E2; TAM, Tyro3 Axl and Mer; R-NOS, reactive nitrogen oxide species; TGFβ, transforming growth factor β; Treg, T-regulatory cell; VEGF, vascular endothelial growth factor.
Adapted with permission from Metpally RPR, et al.45
Journal of Thoracic Oncology  , DOI: ( /j.jtho )
Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions